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Abstract
Background: Many patients with a psychotic disorder participate poorly in society. When psychotic disorders are in
partial remission, feelings of paranoia, delusions of reference, social anxiety and self-stigmatization often remain at
diminished severity and may lead to avoidance of places and people. Virtual reality exposure therapy (VRET) is an
evidence-based treatment for several anxiety disorders. For patients with a psychotic disorder, the VRETp was
developed to help them experience exposure to feared social situations. The present study aims to investigate the
effects of VRETp on social participation in real life among patients with a psychotic disorder.
Methods/design: The study is a single-blind randomized controlled trial with two conditions: the active condition,
in which participants receive the virtual reality treatment together with treatment as usual (TAU), and the waiting
list condition, in which participants receive TAU only. The two groups are compared at baseline, at 3 months
posttreatment and at 6 months follow-up. All participants on the waiting list are also offered the virtual reality
treatment after the follow-up measurements are completed. The primary outcome is social participation. Secondary
outcomes are quality of life, interaction anxiety, depression and social functioning in general. Moderator and
mediator analyses are conducted with stigma, cognitive schemata, cognitive biases, medication adherence,
simulator sickness and presence in virtual reality. If effective, a cost-effectiveness analysis will be conducted.
Discussion: Results from the posttreatment measurement can be considered strong empirical indicators of the
effectiveness of VRETp. The 6-month follow-up data may provide reliable documentation of the long-term effects of
the treatment on the outcome variables. Data from pre-treatment and mid-treatment can be used to reveal
possible pathways of change.
Trial registration: Current Controlled Trials: ISRCTN12929657. Date of registration: 8 September 2015
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Background
A large number of patients with a psychotic disorder
participate poorly in society, even if their psychotic
symptoms have been treated successfully. Unemploy-
ment is high at 80–85 % [1] and about 75 % do not have
a relationship with a partner [2]. A study comparing the
social network of young people with early psychosis and
matched controls showed that the psychosis group had
smaller networks, fewer friends, fewer people to turn to
in a crisis, and a greater likelihood of service providers
as members [3]. Social network size is also associated
with the likelihood of in-patient treatment and with the
number of services used by psychotic patients [4]. Social
isolation hinders patients in multiple areas of function-
ing, such as developing and maintaining a social net-
work, the ability to function in work-related
environments, and even in performing daily tasks
needed for independent living (e.g., shopping for grocer-
ies). When psychotic disorders are in partial remission,
the remaining feelings of paranoia and delusions of ref-
erence often cause patients to avoid places and people.
Moreover, this conditioned avoidance does not improve
with antipsychotic medication [5].
Exposure
The evidence-based psychological treatment for experi-
encing fear and paranoia in social situations is cognitive
behavioral therapy (CBT) with exposure in vivo, such as
the therapist taking a patient shopping or exposing the
patient to public transportation. This form of treatment
in vivo has several limitations. First, the social world in
which in vivo exposure takes place cannot be experi-
mentally manipulated. Second, exposure therapy in vivo
is costly and not readily available in most mental health-
care institutes. Third, therapy sessions are used to pre-
pare exposure exercises, which the patient is expected to
perform between sessions; however, even with careful
tailoring to the patients’ capabilities, it is often difficult
for patients to do these exercises as planned. Fourth, not
all patients tolerate exposure in vivo.
Anxiety disorders and VRET
Virtual reality exposure therapy (VRET) is an evidence-
based treatment for several anxiety disorders [6]. It has
the potential to be an affordable and accessible form of
treatment to enhance social participation and wellbeing
for patients suffering from a psychotic disorder and so-
cial withdrawal. In virtual worlds fear is experienced
similar to the in vivo experience. It is the experience of
being there (known as ‘presence’), which the three-
dimensional virtual reality (VR) environment creates, to-
gether with a narrative about the environment, that en-
ables people to feel and behave as they would in real life.
This principle makes it possible to overcome fear and
practice new behavior in a virtual environment [7]. An
advantage of VR is that people find it easier to start ex-
posure, since they know there is no real threat to their
safety [8]. In students suffering from fear of spiders, 81–
89 % chose VR exposure over in vivo exposure [9]. A
study comparing VR exposure vs. in vivo exposure in
Table 1 Measurement objectives
Outcome Measurement T0 T1 T2 T3 T6
Interview (i) Self-report (s) Baseline Session 4 Session 8 Posttreatment Follow-up
Social participation Experience Sampling Method (s) x x x
Paranoia GPTS (s) x x x x x
Interaction anxiety SIAS (s) x x x x x
Depression BDI-II (s) x x x
Stigma ISMI (s) x x x
Schemas BCSS (s) x x x
Safety behavior SBQ (i) x x x
Cognitive biases DACOBS (s) x x x
Social functioning SOFAS (i) x x x
Quality of life MANSA (i) x x x
Cost-effectiveness TIC-P (i) x x x
Cyber sickness SSQ (s) x x
Presence IPQ (s) x x
Medication adherence BARS (i) x x x x x
GPTS Green et al. Paranoid Thought Scales, SIAS Social Interaction Anxiety Scale, BDI-II Beck Depression Inventory, ISMI Internalized Stigma of Mental Illness, BCSS
Brief Core Schema Scales, SBQ Safety Behavior Questionnaire – persecutory delusions, DACOBS Davos Assessment of Cognitive Biases Scale, SOFAS Social and
Occupational Functioning Assessment Scale, MANSA Manchester Short Assessment of quality of life, TiC-P Trimbos/iMTA questionnaire for Costs associated with
Psychiatric illness, SSQ Simulator Sickness Questionnaire, IPQ Igroup Presence Questionnaire, BARS Brief Adherence Rating Scale
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specific phobias showed that 76 % of the patients chose
VR exposure over in vivo exposure [10]. The refusal rate
for in vivo exposure (27 %) was higher than that for the
VRET (3 %). In total, 90.4 % of the patients that pre-
ferred VR exposure said they did so because they were
too afraid to confront the real situation or to object.
These results suggest that the availability of VR exposure
may increase the number of patients who are willing to
engage in exposure-based therapy.
VRET in psychosis
In a VRET treatment protocol, patients are gradually ex-
posed to controlled social environments that induce fear
and in which individually tailored exposure exercises can
be designed. The ability to provide fear-inducing VR so-
cial environments is partially dependent on the availabil-
ity of anxiety-provoking stimuli in the software of the
virtual worlds. The present study will assess whether the
currently used anxiety-provoking stimuli sufficiently
match the stimuli asked for by patients during
treatment.
An experimental virtual world was developed. The
ecological validity of the VR environment has been dem-
onstrated. For patients suffering from psychosis a signifi-
cant correlation was found between paranoia and social
interaction anxiety in real life and paranoid thoughts
about the avatars in the VR world [11]. A higher degree
of paranoia was found when more avatars were present,
when avatars had hostile facial expressions, and when
more of the avatars had a different ethnicity [12].
Preliminary findings using VRET with psychosis show
that patients experiencing paranoia are willing to partici-
pate in VR environments, that they report paranoid
thoughts about the virtual people (avatars), but at the
same time are willing to confront the fearful situation
[11, 13]. Social virtual environments have the potential
to enhance CBT by helping patients recovering from
psychosis to understand the role of avoidance and safety
behaviors in the maintenance of interaction anxiety and
paranoia. Additionally, it can enhance their confidence
to carry out real-life behavioral experiments [14].
Side effects and safety
A phenomenon called simulator sickness (also known as
cyber sickness) can occur when using VR applications.
Symptoms are similar to those of motion-induced sick-
ness, but tend to be less severe and have a lower inci-
dence [15]. It is suggested that simulator sickness
sensations can be at least partially explained by an over-
lap with anxiety symptoms [16]. A pilot study on virtual
reality and psychosis showed low symptoms of simulator
sickness, and no significant increase between pre- and
post-measurement [11]. Since simulator sickness is
known to increase with the duration of exposure [15],
measurement of these symptoms will be included in the
study protocol.
No adverse effects were found in studies using VR to
expose psychotic patients to virtual social environments.
A study with 20 psychotic patients diagnosed with first-
episode psychosis experiencing at least moderate para-
noia found that VR did not lead to more anxiety or
physical complaints directly after the experiments;
follow-up 1 week later showed that no patients reported
an increase in intrusive negative thoughts, unpleasant
emotions or behavioral changes as a consequence of the
VR experience [16]. Similar results were found in a study
of 21 patients with at-risk mental state for psychosis [8].
Our own pilot study confirmed that patients did not be-
come more psychotic as a result of exposure to our vir-
tual social environment [11].
Objectives
As this is a new form of treatment for social withdrawal in
psychosis, the first step is to demonstrate the effect of
VRET compared to a waiting list condition on social par-
ticipation in real life. Objective social participation is de-
fined as the time spent in social situations with other
people and the time spent interacting with other people in
everyday life. Subjective social participation is how pa-
tients experience these social situations; this experience is
expressed as momentary paranoia, perceived social threat
and event stress, as experienced in situations with other
people.
We hypothesize that, after applying the intervention
for patients with paranoia (VRETp), they will show im-
proved social participation.
Primary objective
To determine the effectiveness of VRETp in patients
with psychosis, defined as improved social participation.
Hypothesis 1: The amount of time spent with other
people will increase, as measured 60 times a week in real
life.
Hypothesis 2: Momentary paranoia, perceived social
threat and event stress as experienced in social situations
will decline, as measured 60 times a week in real life.
Secondary objectives
Secondary objectives are to investigate:
1. the acceptability of VRETp for patients and
therapists
2. the effects on interaction anxiety, depression, quality
of life and social functioning in general
3. the moderating and mediating effects of stigma,
schemata about the self and others, cognitive biases,
medication adherence, simulator sickness and
experienced presence in the VR environment
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4. the cost-effectiveness of VRETp
Methods
Participants
Included are patients diagnosed with a psychotic dis-
order at seven mental health institutions in the
Netherlands: a list of study sites can be obtained from
the corresponding author. Written informed consent is
obtained from each participant.
Inclusion criteria
To be eligible to participate, patients must meet all of
the following criteria:
– DSM IV diagnosis of a psychotic disorder according
to the Mini International Neuropsychiatric Interview
(MINI)
– Avoiding either shops, streets, public transportation
or bars/restaurants as assessed by the Safety
Behavior Questionnaire (SBQ)
– A paranoia score (>40) as assessed by the Green
et al. Paranoid Thoughts Scale (GPTS)
– Age 18–65 years
Exclusion criteria
– IQ ≤70. IQ must be established by a valid
instrument, such as the Wechsler Adult Intelligence
Scale or Wechsler Intelligence Scale for Children.
Information on IQ can be found in the status chart
of the patient. In case of doubt, the short form of
the WAIS III is used to assess IQ
– Insufficient command of the Dutch language
– Epilepsy. If no epilepsy is mentioned in the patient
status, this is checked with the patient
Measurement instruments
Social participation (primary outcome)
Social participation is measured with the PsyMate ex-
perience sampling device. This form of Experience Sam-
pling Measurement (ESM) has high ecological validity
[17]. ESM is a self-assessment technique using random
time sampling, and has the advantage that it can assess
mental state and social context in everyday life as it oc-
curs. Because the ESM assesses ‘at the moment’ it is less
vulnerable for recall bias and a valuable instrument to
assess clinical phenomena in the real world [18]. ESM is
effective for patients with a psychotic disorder with
current symptoms, as well as for patients with a psych-
otic disorder in remission [19]. A review of studies using
the ESM shows it to be valid for measuring situational
characteristics, such as social environment [20]. Event
stress, social environment and company (time spent in
company with others and the kind of company) are
operationalized in accordance with the work of Collip
et al. [19]. Research on the (social) context of delusions
in schizophrenia shows the ESM to be a valid aid in col-
lecting data of daily life social situations [21]. Moment-
ary paranoia, using four established ESM items, is a
valid state measure to assess paranoia [22]. Perceived so-
cial threat, using four established ESM items, is a valid
measure to assess perceived social threat as a more sub-
tle indicator of paranoia [19]. An overview of measure-
ment objectives can be found in Table1.
Eligibility measurements
Psychotic disorders
The MINI-Plus interview is used for diagnosing lifetime
psychotic disorders. This interview provides a reliable
DSM diagnosis for psychotic disorders. The good psy-
chometric characteristics of the MINI (-Plus) make it a
good choice for research purposes [23–25].
Paranoid thoughts
Paranoia symptoms are assessed with the GPTS [26].
The GPTS consists of 32 items divided into two 16-item
scales, assessing ideas of social reference and persecu-
tion. Good internal consistency and validity are estab-
lished for both of the scales and their dimensions [26].
Safety behavior
The Safety Behavior Questionnaire – persecutory delu-
sions (SBQ) is used to assess safety behaviors (such as
avoidance) for social situations [27]. An action was con-
sidered to be safety behavior if the patient reported that
it had been carried out with the aim to reduce a perse-
cutory threat. The patient was asked to rate the fre-
quency of the safety behavior over the last month on a
4-point scale. Psychometric properties of the SBQ range
from poor to excellent [27].
Secondary outcome measures
Quality of life
The Manchester Short Assessment of quality of life
(MANSA) is a brief instrument used to assess quality of
life, focusing on satisfaction with life as a whole and with
life domains. Its psychometric properties are satisfactory
[28].
Interaction anxiety
Interaction anxiety symptoms were assessed with the
Social Interaction Anxiety Scale (SIAS) [29]. The SIAS
consists of 19 items that assess the tendency to fear and
avoid social situations. Responses can range from 0 (not
at all) to 4 (extremely). The SIAS has good psychometric
properties [29, 30].
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Social functioning
The Social and Occupational Functioning Assessment
Scale (SOFAS) is used to subjectively assess and rate so-
cial and occupational functioning, but not psychological
symptoms [31, 32].
Depression
The Beck Depression Inventory-II (BDI-II) consists of
21 items assessing symptoms and level of depression




The Internalized Stigma of Mental Illness (ISMI) is a 29-
item questionnaire that measures self-stigma among
persons with psychiatric disorders. The ISMI shows reli-
ability and validity [34].
Schemata
Schemata of self and others (Brief Core Schema Scales;
BCSS) have 24 items concerning beliefs about the self
and others that are assessed on a 5-point rating scale
(0–4). The BCSS has good psychometric properties [35].
Cognitive biases
The Davos Assessment of Cognitive Biases Scale
(DACOBS) has seven independent subscales each with
six items; jumping to conclusions, belief inflexibility bias,
attention for threat bias, external attribution bias, social
cognition problems, subjective cognitive problems and
safety behavior. The DACOBS is reliable and valid for
use in clinical practice and research [36].
Medication adherence
The Brief Adherence Rating Scale (BARS) is an instru-
ment used to assess the antipsychotic medication adher-
ence of patients with a psychotic disorder. The BARS
consists of four items: three questions and an overall vis-
ual analog rating scale to assess the proportion of doses
taken by the patient in the past month (0–100 %). The
psychometric properties are adequate [37].
Participants and their psychiatrists are asked not to
change any medication during the trial.
Simulator sickness
The Simulator Sickness Questionnaire (SSQ) was devel-
oped to accommodate symptoms specific to simulator
technology. The SSQ requires the user to report the sub-
jective severity of symptoms such as general discomfort,
headache, eyestrain and fatigue [15]. Although its psy-
chometric properties are adequate, there is room for im-
provement [38].
Presence
The Igroup Presence Questionnaire (IPQ) consists of 14
items assessing sense of presence in virtual environ-
ments. Responses are made on a 7-point Likert scale.
The IPQ has demonstrated good psychometric proper-
ties [39].
Cost-effectiveness
The Trimbos/iMTA questionnaire for Costs associated
with Psychiatric illness (the TiC-P) is designed for self-
report by patients with a mental disorder. The question-
naire focuses on establishing direct medical costs and
productivity costs during paid or unpaid work. The psy-
chometric properties are reported to be adequate [40].
Design
The study is a single blind randomized controlled trial
(RCT) with two conditions: (i) the active condition in
which subjects receive the VR treatment besides treat-
ments as usual (TAU) and (ii) the waiting list condition
during which subjects receive TAU only. All participants
on the waiting list are also offered the VR treatment
after follow-up measurements have been completed. The
two groups are compared at baseline, at 3 months post-
treatment and at 6 months follow-up. The waiting list
condition receives the VRET treatment after 6 months.
Power and sample size calculation
In this RCT, the effect of VRETp on social participation
is investigated by comparing this treatment with a wait-
ing list condition. Social participation is assessed with
the PsyMate experience sampling method (ESM; see
“Measurements”). Self-assessments are rated on a 7-
point Likert scale. Main outcome items are social
environment and company, perceived social threat in
company, event stress, and momentary paranoia. Esti-
mated mean scores and standard deviations (SD) are not
readily available because there are no previous VRETp
studies with psychotic patients.
Using an estimated (moderate) effect size of 0.5 with a
power of 0.8, an alpha of 0.05 and a two-sided independ-
ent t test, yields n = 64 in each group. Therefore, at least
64 participants need to be included in each arm (total
n = 128 patients). As attrition is estimated at about 20
%, 80 participants need to be included in each condi-
tion (total n = 160 patients).
Procedure
Patients with a chart diagnosis of schizophrenia,
schizophreniform disorder, schizoaffective disorder, delu-
sional disorder or psychotic disorder not otherwise spe-
cified (NOS), will be informed about the study by their
treating specialist and asked to participate. Each patient
is asked for written permission to be contacted by the
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researchers if eligible for VRETp. If eligible, the treating
specialist discusses participation of the patient in the
study with the remainder of the team and gives permis-
sion to the researchers to contact the patient. When per-
mission is given, additional information is provided and
patients have 2 weeks to consider whether they really
wish to participate. The VRETp treatment is additional
to current treatment and declining to participate has no
negative consequences at all for patients. For each of the
participating organizations an independent specialist is
available for patients to contact. Contact information of
this specialist is available in the information letter given
to the patients of the participating organizations.
Informed consent from all participants is obtained
before assessment by the researcher. The MINI-Plus
interview is used to diagnose psychotic disorders. Pa-
tients who are willing to participate are screened for
avoidance behavior (SBQ) and for paranoia using the
GPTS (cutoff >40) of Green et al. Baseline measure-
ments are obtained. Randomization is used to allocate
a patient to either the VRETP or to the waiting list
condition. Patients allocated to the VRETp group start
their treatment, which consists of a maximum of 16
sessions with a maximum duration of 60 minutes
each.
At baseline (T0) the research assistant assesses the
baseline measurement of all primary and secondary
variables. At 2 weeks (T1) and 4 weeks (T2) into treat-
ment, respectively, participants in the treatment condi-
tion are assessed for their scores on paranoia,
interaction anxiety, cyber sickness, presence in the vir-
tual world and medication adherence, using self-report
questionnaires handed out by the therapist, or interview
questions (medication adherence).
At the end of treatment (T3) and at follow-up (T6),
the research assistant assesses the primary and second-
ary measures.
Randomization
A block of 12 random assignments will be made for
each participating mental health center. Each block
has six assignments for each condition: VRETp or
waiting list. If a center includes more patients, new
blocks of 12 random assignments will be made avail-
able. The blocks are made using a scientific
randomization program (www.randomizer.org) by the
independent randomization bureau of Parnassia Psy-
chiatric Institute. Participants and therapists are in-
formed about the randomization by mail and email,
respectively.
Interventions
Figure 1 is a flow diagram showing study inclusion.
Fig. 1 Flow diagram of virtual reality exposure therapy for patients with psychosis (VRETp). A figure showing the flow of patients in the study protocol
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Treatment as usual (TAU)
Participants in both the VRETp and the waiting list con-
dition receive TAU, consisting of antipsychotic medica-
tion, and treatment and/or supportive counseling by
therapists, caseworkers or coaches. TAU is considered to
be equal in both conditions as a result of the
randomization procedure used (see “Randomization”).
During the trial participants are not allowed to receive
any therapy aimed at improving social participation.
Virtual reality exposure therapy (VRET)
VRETp treatment has a maximum of 16 treatment ses-
sions of 60 minutes each. This number of sessions is
somewhat larger than is usual for CBT in anxiety disor-
ders. Our rationale for this is our expectation that treat-
ing paranoia requires more time compared with treating
regular anxiety. People suffering from a psychotic dis-
order often show severity and durance in their social
avoidance. Negative symptoms make it difficult to mo-
tivate people for therapy and this is a continuing process
during treatment. The treatment protocol states that the
therapists receive 16 hours of training; all therapy ses-
sions are recorded. A selection of the sessions is rated
for treatment fidelity using the Cognitive Therapy Rating
Scale (CTRS). The CTRS is a reliable [41] and valid [42]
instrument to measure treatment fidelity when following
a CBT protocol. Monthly 4-hour group supervision
serves to guide the therapists throughout the interven-
tion period.
Existing CBT protocols will be adapted for VRET
treatment in one area: exposure in vivo will be replaced
by VR exposure. The remainder of the treatment proto-
col consists of well-known, evidence-based CBT ele-
ments, e.g., providing treatment rationale, behavioral
experiments, reducing safety behavior, and attention
training. Starting with exposure exercises for social situ-
ations, which are lowest in the patient’s anxiety hier-
archy, the exposure exercises take place during the
therapy session using the Virtual Reality system. Partici-
pants are not allowed to receive any other form of ther-
apy aimed at improving social participation during the
trial. At all times the therapist is in control of the
VRETp intervention and is able to immediately change/
stop the virtual environment if necessary.
Early completions
A participant is considered an early completer of
treatment when the subjective units of distress on a
scale of 0 (no stress at all) to 100 (extremely stressful) in
all the virtual situations that are part of the case
conceptualization are reduced to zero in two consecutive
sessions. This criterion is restrictive and was chosen to
prevent therapies being ended prematurely, since no
point of reference has been established for treating para-
noia using VR exposure.
Discontinuation
Participation is completely voluntary and participants
can withdraw from participation at any time for any rea-
son. Participants who drop out or otherwise deviate
from the intervention protocol are requested to continue
to participate in the measurements.
Fidelity checks
Audiotapes are made of all sessions and a selection of
them is rated for treatment fidelity. All therapists are su-
pervised by a highly skilled professional (MvdG) to
evaluate, guide and approve the case conceptualization.
Every 6 weeks, 4-hour group supervision supports the
therapist for the duration of the intervention. By means
of a questionnaire, for each session the therapist reports
on the elements and steps in the treatment protocol.
Any deviation from the protocol is reported to the
supervisor.
Unblinding
The study is single-blinded, meaning that research assis-
tants who do the measurements are kept blinded regard-
ing randomization of the participants. Participants are
regularly instructed not to tell the research assistants
which group they are allocated to; if a research assistant
is accidentally unblinded during a measurement, that
measurement is stopped. A new appointment is then
made with another blinded research assistant.
Adverse events
The rules and regulations of the Medical Ethics
Committee concerning adverse events are followed. All
participants are insured in case any harm is caused re-
lated to trial participation.
Analyses
Data management
All data are directly coded with a number. Data and per-
sonal information of the participants are kept separately
and safely stored to ensure privacy. All data entry is
double-checked. A data monitor from Parnassia Psychi-
atric Institute is appointed for the study.
Data analysis
Multilevel linear mixed modeling is used to analyze the
data according to the intention-to-treat principle. Com-
pleter analysis is conducted with analysis of variance
(ANCOVA). Moderator and mediator analysis is con-
ducted to assess the effects of moderators and media-
tors. Cost-effectiveness is conducted with social
participation as the outcome.
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Ethics
Ethical approval of the protocol was granted by De
Medisch Ethische Toetsingscommissie VU medisch cen-
trum (METC number: NL37356.058.12).
Discussion
The main goal of the study is to investigate the effect of
VRETp on improving social participation in patients
with psychosis in real life. We hypothesize that VRETp
will increase social participation objectively (time spent
in company) and subjectively (experience less anxiety
and paranoia during in social situations). Comparison
between VRETp treatment and a waiting list condition
will provide information about the effectiveness of VR
exposure therapy for this population. This should make
an important contribution to treatment options for
people suffering from psychosis and social isolation. Im-
proving social participation is of great personal value to
patients with psychosis who suffer from the conse-
quences of avoiding social situations in daily life.
In addition to social participation, the effect of VRETp on
psychological, emotional and social well-being, especially
paranoia and interaction anxiety, is explored. Studying these
variables may help disentangle the complex phenomena re-
lated to social participation in patients with psychosis.
Another aspect of the study is cost-effectiveness. If so-
cial participation improves it is expected that patients
will become more independent, consume less care and,




BARS: Brief Adherence Rating Scale; BCSS: Brief Core Schema Scales; BDI-
II: Beck Depression Inventory; CBT: Cognitive behavioral therapy;
CTRS: Cognitive Therapy Rating Scale; DACOBS: Davos Assessment of
Cognitive Biases Scale; ESM: Experience Sampling Measurement; GPTS: Green
et al. Paranoid Thought Scales; IC: Informed consent; IPQ: Igroup Presence
Questionnaire; ISMI: Internalized Stigma of Mental Illness;
MANSA: Manchester Short Assessment of quality of life; MINI: Mini
International Neuropsychiatric Interview; RCT: Randomized controlled trial;
SBQ: Safety Behavior Questionnaire – persecutory delusions; SIAS: Social
Interaction Anxiety Scale; SOFAS: Social and Occupational Functioning
Assessment Scale; SSQ: Simulator Sickness Questionnaire; TAU: Treatment as
usual; TiC-P: Trimbos/iMTA questionnaire for Costs associated with Psychiatric
illness; WAIS: Wechsler Adult Intelligence Scale; WISC: Wechsler Intelligence
Scale for Children; VR: Virtual reality; VRET: Virtual reality exposure therapy;
VRETp: Virtual reality exposure therapy for patients with psychosis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to both the design and implementation of the study.
MvdG is the principal investigator of the study and supervises the
development of the study protocol. RP-K is responsible for the logistics
within the departments of the psychiatric centers: she organizes and
supervises the process of patient recruitment, training and managing the
research assistants, and monitoring and supervising the research reports on
assessment and diagnosis. MvdG and WV supervise the development of the
treatment protocols and the standardized case conceptualization format by
RP-K. MvdG supervises therapists individually in case conceptualization and
in group-wise treatment supervision. RP-K prepares the manuals for
therapists and research assistants. All authors (MvdG, WV, RP-K, and CG)
provide comments on all aspects of the study, and read and approved the
final manuscripts. All authors have complete access to the final trial dataset.
Trial results will be communicated via publication. All authors have read and
approved the final version of this manuscript.
Authors’ information
Roos Pot-Kolder is a psychologist and PhD student at the VU University
Amsterdam, The Netherlands. She works at Parnassia Psychiatric Institute,
Den Haag, The Netherlands in a team for the treatment of first-episode
psychosis. Mark van der Gaag is professor of Clinical Psychology at the VU
University and EMGO Institute for Health and Care Research, Department of
Clinical Psychology, Amsterdam, The Netherlands. He is head of Psychosis
Research at Parnassia Psychiatric Institute, The Netherlands. Wim Veling is a
psychiatrist and assistant professor at the University of Groningen, University
Medical Center Groningen (UMCG), The Netherlands. He is head of the
Psychosis Department of the University Center of Psychiatry, UMCG. Chris
Gereats is a PhD student at the University of Groningen, University Medical
Center Groningen, the Netherlands.
Acknowledgments
The VRETp trial is supported by ZonMw and by NutsOhra.
The authors thank all participants of this study, without whom this trial
would not be possible. We are greatly indebted to Marion Bruns, Alyssa
Jongeneel and Nicolien Savelsberg, data and research monitors, for their
tremendous efforts in preparing and timing the flow of measurements, and
data collection and monitoring during the study. We thank all research
assistants, therapists, local researchers, independent specialists, advisors and
all others who helped bring this study to a successful conclusion. We also
thank Tonnie Staring for his work on the VRETp treatment protocol. Finally, we
thank Professor Philippe Delespaul for his help in the setup and operational
and analytical instruction of the Experience Sampling Measurement.
Author details
1Parnassia Psychiatric Institute, Zoutkeetsingel 40, 2512 HN Den Haag, The
Netherlands. 2Department of Clinical Psychology, VU University and EMGO
Institute for Health and Care Research, Van der Boechorststraat 1, 1081 BT
Amsterdam, The Netherlands. 3University of Groningen, UMC Groningen,
University Center of Psychiatry, Hanzeplein 1, 9700 RB Groningen, The
Netherlands.
Received: 12 July 2015 Accepted: 21 December 2015
References
1. Perkins R. Unemployment rates among patients with long-term mental
health problems: a decade of rising unemployment. Psychiatr Bull. 2002;26:
295–8. doi:10.1192/pb.26.8.295.
2. Nyer M, Kasckow J, Fellows I, Lawrence EC, Golshan S, Solorzano E, et al.
The relationship of marital status and clinical characteristics in middle-aged
and older patients with schizophrenia and depressive symptoms. Ann Clin
Psychiatry. 2010;22:172–9.
3. Macdonald EM, Hayes RL, Baglioni AJ. The quantity and quality of social
networks of young people with early psychosis compared with closely
matched controls. Schizophr Res. 2000;46:25–30.
4. Becker T, Thornicroft G, Leese M, Mccrone P, Johnson S, Albert M, et al.
Social networks and service use among representative cases of psychosis in
south London. Br J Psychiatry. 1997;171:15–9.
5. Moutoussis M, Williams J, Dayan P, Bentall RP. Persecutory delusions and
the conditioned avoidance paradigm: towards an integration of the
psychology and biology of paranoia. Cogn Neuropsychiatry. 2007;12:495–
510. doi:10.1080/13546800701566686.
6. Opriş D, Pintea S, García-Palacios A, Botella C, Szamosközi Ş, David D. Virtual
reality exposure therapy in anxiety disorders: a quantitative meta-analysis.
Depress Anxiety. 2012;29:85–93. doi:10.1002/da.20910.
7. Gorini A, Capideville CS, De Leo G, Mantovani F, Riva G. The role of
immersion and narrative in mediated presence: the virtual hospital
experience. Cyberpsychol Behav Soc Netw. 2011;14:99–105. doi:10.1089/
cyber.2010.0100.
Pot-Kolder et al. Trials  (2016) 17:25 Page 8 of 9
8. Valmaggia LR, Freeman D, Green C, Garety P, Swapp D, Antley A, et al.
Virtual reality and paranoid ideations in people with an ‘at-risk mental state’
for psychosis. Br J Psychiatry. 2007;191:S63–8.
9. Garcia-Palacios A, Hoffman HG, See SK, Tsai A, Botella C. Redefining
therapeutic success with virtual reality exposure therapy. Cyberpsychol
Behav. 2001;4:341–8.
10. Garcia-Palacios A, Botella C, Hoffman H, Fabregat S. Comparing acceptance
and refusal rates of virtual reality exposure vs. in vivo exposure by patients
with specific phobias. Cyberpsychol Behav. 2007;10:722–4. doi:10.1089/cpb.
2007.9962.
11. Veling W, Brinkman W-P, Dorrestijn E, van der Gaag M. Virtual reality
experiments linking social environment and psychosis: a pilot study.
Cyberpsychol Behav Soc Network. 2014;17:191–5. doi:10.1089/cyber.2012.0497.
12. Brinkman W-P, Veling W, Dorrestijn E, Sandino G, Vakili V, Van der Gaag M.
Virtual reality to study responses to social environmental stressors in
individuals with and without psychosis. Stud Health Tech Informatics. 2011;
167:86–91. doi:10.3233/978-1-60750-766-6-86.
13. Freeman D, Slater M, Bebbington PE, Garety PA, Kuipers E, Fowler D, et al.
Can virtual reality be used to investigate persecutory ideation? J Nerv Ment
Dis. 2003;191:509–14. doi:10.1097/01.nmd.0000082212.83842.fe.
14. Gega L, White R, Clarke T, Turner R, Fowler D. Virtual environments using
video capture for social phobia with psychosis. Cyberpsychol Behav Soc
Network. 2013;16:473–9. doi:10.1089/cyber.2013.1510.
15. Kennedy RS, Lane NE, Berbaum KS, Lilienthal MG. Simulator sickness
questionnaire: an enhanced method for quantifying simulator sickness. Int J
Aviat Psychol. 1993;3:203–20.
16. Fornells-Ambrojo M, Barker C, Swapp D, Slater M, Antley A, Freeman D.
Virtual reality and persecutory delusions: safety and feasibility. Schizophr
Res. 2008;104:228–36. doi:10.1016/j.schres.2008.05.013.
17. Kimhy D, Myin-Germeys I, Palmier-Claus J, Swendsen J. Mobile assessment
guide for research in schizophrenia and severe mental disorders. Schizophr
Bull. 2012;38:386–95. doi:10.1093/schbul/sbr186.
18. Palmier-Claus JE, Myin-Germeys I, Barkus E, Bentley L, Udachina A, Delespaul
PAEG, et al. Experience sampling research in individuals with mental illness:
reflections and guidance. Acta Psychiatr Scand. 2011;123:12–20. doi:10.1111/
j.1600-0447.2010.01596.x.
19. Collip D, Oorschot M, Thewissen V, Van Os J, Bentall R, Myin-Germeys I.
Social world interactions: how company connects to paranoia. Psychol Med.
2010;41:911–21. doi:10.1017/s0033291710001558.
20. Oorschot M, Kwapil T, Delespaul P, Myin-Germeys I. Momentary assessment
research in psychosis. Psychol Assess. 2009;21:498–505.
21. Myin-Germeys I, Nicolson NA, Delespaul PA. The context of delusional
experiences in the daily life of patients with schizophrenia. Psychol Med.
2001;31:489–98.
22. Thewissen V, Bentall RP, Lecomte T, van Os J, Myin-Germeys I. Fluctuations
in self-esteem and paranoia in the context of daily life. J Abnorm Psychol.
2008;117:143–53. doi:10.1037/0021-843x.117.1.143.
23. Amorim P, Lecrubier Y, Weiller E, Hergueta T, Sheehan D. DSM-III-R
psychotic disorders: procedural validity of the Mini International
Neuropsychiatric Interview (MINI). Concordance and causes for discordance
with the CIDI. Eur Psychiatry. 1998;13:26–34.
24. Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Keskiner A,
et al. The validity of the Mini International Neuropsychiatric Interview (MINI)
according to the SCID-P and its reliability. Eur Psychiatry. 1997;12:232–41.
doi:10.1016/S0924-9338(97)83297-X.
25. Van Vliet IM, De Beurs E. The MINI-International Neuropsychiatric Interview.
A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10
psychiatric disorders. Tijdschrift voor Psychiatrie. 2007;49:393–7.
26. Green CEL, Freeman D, Kuipers E, Bebbington P, Fowler D, Dunn G, et al.
Measuring ideas of persecution and social reference: the Green et al.
Paranoid Thought Scales (GPTS). Psychol Med. 2007;38:101–11. doi:10.1017/
s0033291707001638.
27. Freeman D, Garety PA, Kuipers E. Persecutory delusions: developing the
understanding of belief maintenance and emotional distress. Psychol Med.
2001;31:1293–306. doi:10.1017/s003329170100455x.
28. Priebe S, Huxley P, Knight S, Evans S. Application and results of the
Manchester Short Assessment of quality of life (MANSA). Int J Soc
Psychiatry. 1999;45:7–12.
29. Mattick RP, Clarke JC. Development and validation of measures of social
phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998;36:
455–70.
30. Heidenreich T, Schermelleh-Engel K, Schramm E, Hofmann SG, Stangier U. The
factor structure of the social interaction anxiety scale and the social phobia
scale. J Anxiety Disord. 2011;25:579–83. doi:10.1016/j.janxdis.2011.01.006.
31. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of
measures of social functioning. Am J Psychiatry. 1992;149:1148–56.
32. Samara MT, Engel RR, Millier A, Kandenwein J, Toumi M, Leucht S.
Equipercentile linking of scales measuring functioning and symptoms:
examining the GAF, SOFAS, CGI-S, and PANSS. Eur Neuropsychopharmacol.
2014;24:1767–72. doi:10.1016/j.euroneuro.2014.08.009.
33. Roelofs J, van Breukelen G, de Graaf LE, Beck AT, Arntz A, Huibers MJH.
Norms for the Beck Depression Inventory (BDI-II) in a large Dutch
community sample. J Psychopathol Behav Assess. 2012;35:93–8. doi:10.1007/
s10862-012-9309-2.
34. Boyd JE, Adler EP, Otilingam PG, Peters T. Internalized Stigma of Mental
Illness (ISMI) Scale: a multinational review. Compr Psychiatry. 2014;55:221–
31. doi:10.1016/j.comppsych.2013.06.005.
35. Fowler D, Freeman D, Smith BEN, Kuipers E, Bebbington P, Bashforth H,
et al. The Brief Core Schema Scales (BCSS): psychometric properties and
associations with paranoia and grandiosity in non-clinical and psychosis
samples. Psychol Med. 2006;36:749–59. doi:10.1017/s0033291706007355.
36. van der Gaag M, Schütz C, ten Napel A, Landa Y, Delespaul P, Bak M, et al.
Development of the Davos Assessment of Cognitive Biases Scale (DACOBS).
Schizophr Res. 2013;144:63–71. doi:10.1016/j.schres.2012.12.010.
37. Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS)
validated against electronic monitoring in assessing the antipsychotic
medication adherence of outpatients with schizophrenia and schizoaffective
disorder. Schizophr Res. 2008;100:60–9. doi:10.1016/j.schres.2007.12.470.
38. Bruck S, Watters PA. The factor structure of cybersickness. Displays. 2011;32:
153–8. doi:10.1016/j.displa.2011.07.002.
39. Thomas S, Regenbrecht H, Friedmann F. The experience of presence: factor
analytic insights. Presence: Teleoperators Virtual Environ. 2001;10:266–81.
40. Bouwmans C, De Jong K, Timman R, Zijlstra Vlasveld M, Van Der Feltz-
Cornelis C, Swan Tan S, et al. Feasibility, reliability and validity of a
questionnaire on healthcare consumption and productivity loss in patients
with a psychiatric disorder (TiC-P). BMC Health Serv Res. 2013;13:217. doi:10.
1186/1472-6963-13-217.
41. Vallis TM, Shaw BF, Dobson KS. The cognitive therapy scale: psychometric
properties. J Consult Clin Psychol. 1986;54:381–5.
42. Shaw BF, Elkin I, Yamaguchi J, Olmsted M, Vallis TM, Dobson KS, et al.
Therapist competence rating in relation to clinical outcome in cognitive
therapy of depression. J Consult Clin Psychol. 1999;67:837–46.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pot-Kolder et al. Trials  (2016) 17:25 Page 9 of 9
